Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.3474
+0.0177 (5.37%)
At close: Apr 8, 2026, 4:00 PM EDT
0.3400
-0.0074 (-2.13%)
After-hours: Apr 8, 2026, 7:46 PM EDT
Gossamer Bio Revenue
In the year 2025, Gossamer Bio had annual revenue of $48.47M, down -57.74%. Gossamer Bio had revenue of $13.80M in the quarter ending December 31, 2025, with 47.13% growth.
Revenue (ttm)
$48.47M
Revenue Growth
-57.74%
P/S Ratio
1.68
Revenue / Employee
$299,204
Employees
162
Market Cap
81.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.47M | -66.23M | -57.74% |
| Dec 31, 2024 | 114.70M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 63.26M |
| Pelthos Therapeutics | 16.80M |
| Rani Therapeutics Holdings | 1.63M |
| NRx Pharmaceuticals | 1.23M |
| aTyr Pharma | 190.00K |
GOSS News
- 22 days ago - Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update - Business Wire
- 4 weeks ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1 - Benzinga
- 5 weeks ago - GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 6 weeks ago - BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75% - GlobeNewsWire
- 6 weeks ago - Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 6 weeks ago - Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks - Benzinga
- 6 weeks ago - Gossamer Bio's experimental lung condition drug fails in late-stage trial - Reuters
- 6 weeks ago - Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - Business Wire